Biocytogen and Merck KGaA Collaborate on Targeted Nucleic Acid Delivery Using Antibody-Conjugated LNPs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 04 2025
0mins
Source: NASDAQ.COM
Partnership Announcement: Biocytogen Pharmaceuticals and Merck KGaA have entered into an evaluation and option agreement to develop antibody-conjugated lipid-based delivery solutions for nucleic acid payloads.
Terms of the Agreement: Biocytogen will provide human antibodies from its RenMice platform, while Merck KGaA has the option to acquire rights to selected antibody assets in exchange for fees and royalties.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
